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Abstract
Insulin produces an influx of Ca2 into isolated rat hepatocyte couplets that is important to couple its tyrosine kinase
receptor to MAPK activity (Benzeroual et al., Am. J. Physiol. 272, (1997) G1425^G1432. In the present study, we have
examined the implication of Ca2 in the phosphorylation state of the insulin receptor (IR) L-subunit and of insulin receptor
substrate-1 (IRS-1), as well as in the stimulation of PI 3-kinase activity in cultured hepatocytes. External Ca2 chelation
(EGTA 4 mM) or administration of Ca2 channel inhibitors gadolinium 50 WM or nickel 500 WM inhibited insulin-induced
PI 3-kinase activation by 85, 50 and 50%, respectively, whereas 200 WM verapamil was without effect. In contrast, the insulin-
induced tyrosine phosphorylation of IR L-subunit and of IRS-1 was not affected by any of the experimental conditions. Our
data demonstrate that the stimulation of PI 3-kinase activity by the activated insulin receptor, but not the phosphorylation of
IR L-subunit and IRS-1, requires an influx of Ca2. Ca2 thus appears to play an important role as a second messenger in
insulin signaling in liver cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
At the cellular level, insulin promotes a wide vari-
ety of biological functions, including stimulation of
amino acid and glucose transport, modulation of en-
zyme activities and of gene expression, and enhance-
ment of DNA synthesis [1]. Through these events,
insulin acts as a central regulator in glucose, lipid
and protein metabolism in liver and other peripheral
tissues in response to environmental changes.
Signaling through the insulin receptor is a complex
process that involves the activation of protein ki-
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nases and phosphatases, principally in at least two
major transduction systems: one involving mitogen-
activated protein kinase (MAP kinase) and another
involving phosphatidylinositol 3-kinase (PI 3-kinase).
In most cells, insulin initiates its e¡ects by interacting
with the K-subunit of its receptor with subsequent
activation of the tyrosine kinase activity of the L-
subunit followed by receptor autophosphorylation
[1,2]. Activation of the insulin receptor (IR) tyrosine
kinase also leads to tyrosyl phosphorylation of a
number of intracellular proteins, the most prominent
being the cytosolic insulin receptor substrate-1 (IRS-
1) [3]. Considerable evidence demonstrates that IR
tyrosine kinase activity and associated IRS-1 phos-
phorylation are essential for many of the complex
cellular responses to insulin [1,4,5].
IRS-1 acts as an intermediate docking protein be-
tween the IR and cytoplasmic proteins containing
SH2 domains [3]. For instance, when IRS-1 is tyro-
sine phosphorylated, it can bind and activate PI
3-kinase in several cells in vivo and in vitro, including
the liver [3,6^9]. This enzyme is composed of a 85-
kDa regulatory subunit [10] and a 110-kDa catalytic
subunit that phosphorylates phosphatidylinositol
(PI) as well as its 4 and 4,5 phosphorylated deriva-
tives in the D-3 position of the inositol ring [11]. PI
3-kinase plays a key role in mediating several bio-
logical e¡ects of insulin, such as glucose transport
[12], glycogen synthesis [13], and transcriptional reg-
ulation of several genes [14,15]. Thus, IR, IRS-1, and
PI 3-kinase represent three of the earliest steps in one
branch of the insulin signaling cascade.
In the liver, insulin is also known to promote cat-
ion in£ux and this was found to be important for the
hormone’s action [16]. Moreover, we have recently
demonstrated that insulin induces an increase in cy-
tosolic Ca2 in primary rat hepatocytes. This in-
crease was dependent on the presence of external
Ca2 but was independent of e¡ects on insulin bind-
ing [17]. It also had a pharmacological sensitivity
reminiscent of non-selective cation channels present
on the hepatocyte plasma membrane [18,19]. Finally,
conditions interfering with the e¡ect of insulin on
hepatocellular Ca2 were also found to inhibit the
stimulation of MAPK activity by the hormone. We
concluded that insulin triggers Ca2 in£ux into liver
cells and this e¡ect is important for the stimulation
of the MAPK signaling cascade [17].
The question of the implication of Ca2 in other
pathways of insulin action in the liver thus arose.
Therefore, the aim of the present work was to exam-
ine the implication of Ca2 in the other major branch
of the insulin signal transduction pathway, namely
PI 3-kinase activation. To gain further insight on
the site of action of the divalent cation, we also ex-
amined the e¡ect of Ca2 on the phosphorylation
state of the IR L-subunit and of IRS-1.
2. Materials and methods
2.1. Materials
Gadolinium chloride hexahydrate was purchased
from Aldrich (Milwaukee, WI). Polyclonal antibody
against the p85 regulatory subunit of PI 3-kinase was
purchased from Santa Cruz Biotechnology, (Santa
Cruz, CA); it is directed against an epitope corre-
sponding to amino acids 333^430 of the protein.
Anti-phosphotyrosine, anti-human insulin receptor
L-subunit and anti-rat carboxyterminal IRS-1 anti-
bodies were purchased from Upstate Biotechnology
(Lake Placid, NY). Goat anti-mouse antibodies con-
jugated to alkaline phosphatase were from Bio-Rad
(Mississauga, ON). Silica gel-60 plates were pur-
chased from Merck (Rahway, NJ). Protein A Se-
pharose beads were obtained from Pharmacia Bio-
tech (Mississauga, ON). Bovine insulin, bovine
serum albumin (BSA fraction V), leupeptin, aproti-
nin, pepstatin A, as well as other chemicals were
purchased from Sigma-Aldrich (Oakville, ON).
2.2. Animals
Male Sprague^Dawley rats weighing 150^175 g
were ordered from Charles River Breeding Labora-
tories (St.-Constant, QC) and allowed free access to
Purina rat chow and tap water. Animals were treated
in accordance with the guidelines of the Canadian
Council for the Care of Animals and all experimental
protocols were accepted by the university ethics com-
mittee.
2.3. Isolation and incubation of hepatocytes
Rats were anesthetized with an intraperitoneal in-
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jection of sodium pentobarbital (50 mg/kg; Centre de
Distribution de Me¤dicaments Ve¤te¤rinaires, St.-Hya-
cinthe, QC) prior to surgery. Hepatocytes were iso-
lated by collagenase digestion of the liver as previ-
ously described [20]. Cells were puri¢ed by
centrifugation on a Percoll gradient. Viability was
determined by Trypan blue exclusion and exceeded
85%. Freshly isolated hepatocytes were suspended in
William’s E medium containing 25 mM bicarbonate
and 1% BSA, pH 7.4, at 37‡C. Cells were then seeded
onto 35-mm plastic Petri dishes previously coated
with rat tail collagen. Thereafter, cells were incu-
bated for 60 min at 37‡C in a humidi¢ed atmosphere
of 5% CO2^95% O2. Unattached cells were then re-
moved, medium was replaced with Krebs-Henseleit
bu¡er, and incubation was prolonged for an addi-
tional 30 min. These conditions are similar to £uo-
rescence experiments where insulin was found to in-
crease intracellular calcium [17].
2.4. PI 3-kinase assay
The assay was performed essentially as described
by Fukui and Hanafusa [21] with minor modi¢ca-
tions [22]. Isolated hepatocytes were cultured as de-
scribed above. Cells were challenged at 37‡C with
Krebs^Henseleit bu¡er containing insulin or its ve-
hicle. To assess the e¡ects of 4 mM EGTA, 200 WM
verapamil, 500 WM nickel or 50 WM gadolinium,
these agents were administered 15 min before and
throughout the insulin challenge. The incubation
was stopped by two rapid washes with ice-cold phos-
phate-bu¡ered saline. The 35-mm Petri dishes were
then quickly frozen on liquid nitrogen and stored at
380‡C pending the enzyme assay. The cells were
lysed in bu¡er A (25 mM Tris-HCl, pH 7.5, 25
mM NaCl, 1 mM Na orthovanadate, 10 mM Na
£uoride, 10 mM Na pyrophosphate, 20 nM okadaic
acid, 0.5 mM EDTA, 1 mM phenylmethylsulfonyl
£uoride (PMSF), 10 Wg/ml aprotinin, 1% Triton X-
100 and 0.1% SDS). The cells were scraped and cen-
trifuged at 12 000Ug for 12 min. Equal amount of
lysate proteins were incubated with 5 Wl of p85-anti-
body for 2 h at 4‡C. Protein A-Sepharose beads were
then added and the resulting mixture was incubated
for an additional 2 h at 4‡C. The beads were centri-
fuged in a microtube for 15 s and the pellet was
washed three times with HNTG medium (20 mM
HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-
100, 10% Glycerol, 10 Wg/ml leupeptin, 1 mM
PMSF), once with 0.5 M LiCl/0.1 M Tris pH 7.5,
once with H2O and ¢nally with 0.1 M NaCl/1 mM
EDTA/20 mM Tris pH 7.5. Beads were then resus-
pended in 50 Wl of kinase bu¡er (20 mM Tris-HCl,
pH 7.5, 10 mM NaCl, 0.5 mM EGTA). Then 1 Wl of
a 20 mg/ml concentration of pure L-K-phosphatidyl-
inositol (PI) (bought from Sigma) dissolved in DMSO
was added to the reaction mixture to make micelles
of PI. The mixture was vortexed and preincubated at
room temperature for 10 min. Subsequently, [Q-32P]-
ATP (2 mCi/ml) (10 WCi per assay) and MgCl2
(10 mM) were added to start the reaction and the
mixture was incubated for 2^3 min at room temper-
ature. The reaction was stopped by addition of 150 Wl
of CHCl3 : CH3OH: HCL (100:200:2) and 100 Wl
of CHCl3 was added to separate the phases. The
inferior organic phase was taken and washed with
one volume of CH3OH:HCl (1:1). The lipid samples
were concentrated in vacuo and spotted onto a silica
gel 60 plate which was later developed in CHCl3 :
CH3OH:NH4OH:H2O (43:38:5:7). The phosphory-
lated lipids were visualized by autoradiography and
the area corresponding to each spot was quanti¢ed
by using a phophorimager (Molecular Dynamics). A
similar method has been used by other investigators
to demonstrate insulin-stimulated PI 3-kinase activity
in CHO cells [23] and adipocytes [24].
2.5. Insulin receptor L-subunit tyrosine
phosphorylation
The cells were stimulated as described for PI
3-kinase assay and were lysed on ice in 200 Wl of
bu¡er A. The lysates were clari¢ed by centrifugation
for 12 min at 10 000Ug and then incubated over-
night at 4‡C with 5 Wl of anti-human IR L-subunit
antibody preadsorbed to protein A-Sepharose beads.
The immunoprecipitate was collected with protein A-
Sepharose and washed three times, once with 50 mM
HEPES bu¡er, pH 7.5, containing 0.1% Triton X-
100 and 0.1% SDS and twice with the same bu¡er
without SDS. The immunoprecipitate was solubilized
by boiling in 2Usample bu¡er for 10 min. The solu-
bilized fraction was submitted to electrophoresis on
10% SDS-polyacrylamide gels and blotted with anti-
phosphotyrosine antibody (1:1000). The blots were
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developed by using goat-anti-mouse IgG conjugated
to alkaline phosphatase (1:3000) [25].
2.6. IRS-1 tyrosine phosphorylation
Cells were stimulated and lysed as described
above. Equal amounts of protein from cell lysates
were added to the anti-IRS-1 antibody-protein A-Se-
pharose complex and incubation continued overnight
at 4‡C. The immunoprecipitate was collected by cen-
trifugation in a microtube for 15 s and the pellet was
washed three times with ice-cold PBS. The beads
were boiled in 3ULaemmli’s sample bu¡er, submit-
ted to electrophoresis on 10% SDS-polyacrylamide
gels, transferred to PVDF membranes, blotted with
anti-phosphotyrosine antibody (1:1000) and detected
by goat-anti-mouse IgG conjugated to alkaline phos-
phatase (1:3000) [22].
2.7. Statistical analysis
Results are expressed as means þ S.E.M. Statistical
signi¢cance between treatment groups was evaluated
by one-way analysis of variance. Di¡erences between
group means were considered signi¢cant at P6 0.05.
3. Results
3.1. Time-dependence of PI 3-kinase activity
We ¢rst evaluated the time course of PI 3-kinase
activity in response to insulin in primary cultures of
rat hepatocytes, as it had not been directly examined
in this model previously. Fig. 1 presents the results of
experiments where hepatocytes were stimulated with
10 nM insulin for the indicated times. PI 3-kinase
was then immunoprecipitated by using antibodies
to the p85 subunit of the enzyme. Immune complexes
were subjected to PI 3-kinase assay as detailed in the
Section 2. As expected, insulin caused a time-depen-
dent increase in PI 3-kinase activity. The e¡ect of
insulin was evident as early as 1 min and maximal
at 3 min. Thereafter, PI 3-kinase activity remained
elevated for at least 15 min after exposure to the
hormone. The duration of insulin’s e¡ect on PI
3-kinase in primary hepatocytes was similar to that
reported in CHO cells [23] and in adipocytes [24].
3.2. Dose-dependence of PI 3-kinase activity
Similarly, the concentration dependence of the in-
sulin action on PI 3-kinase activity in cultured rat
hepatocytes had not been reported. Therefore, pri-
mary hepatocytes were stimulated with increasing
concentrations of insulin (0.1^100 nM) for 3 min.
As shown in Fig. 2, an increase in PI 3-kinase activ-
ity was detectable after exposure to 0.1 nM insulin
(1.5-fold stimulation above basal values) and optimal
stimulation was observed with 10 nM insulin (4-fold
stimulation), as seen for several other insulin-depen-
dent actions in such preparations [26,27]. When the
data were ¢tted for a standard dose^response rela-
tionship, a half-maximal e¡ective dose of 1.1 þ 0.5
nM insulin was obtained which falls within the phys-
iological range [28]. Thus, insulin-induced stimula-
tion of PI 3-kinase in isolated cultured hepatocytes
was dose-dependent as previously observed in whole
liver [29] and in isolated adipocytes [24].
3.3. E¡ect of Ca2+ on insulin-induced PI 3-kinase
activity
Since interference with Ca2 movements was pre-
Fig. 1. Time course of stimulation of PI 3-kinase activity by in-
sulin. Isolated rat hepatocytes were incubated in the presence of
10 nM insulin for 1, 3, 5, 10, and 15 min. Cells were lysed and
the protein lysates were immunoprecipitated with p85-antibody
as described in Section 2. The immune complex was assessed
for PI 3-kinase activity using phosphatidylinositol as substrate
as described in Section 2. Data points are the mean þ S.E.M. of
eight separate experiments and are expressed in relation to re-
spective baseline values obtained for each experiment (di¡erent
hepatocyte preparation).
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viously shown to prevent insulin-stimulated MAPK
activity [17], we were interested to explore if Ca2
was also implicated in other insulin-stimulated path-
ways. As presented above, an optimal increase in
hepatocyte PI 3-kinase activity was observed once
the cells were stimulated with 10 nM insulin for
3 min (Figs. 1 and 2). We thus used these conditions
to examine the e¡ects of external Ca2 chelation and
of Ca2 channel inhibition. As shown in Fig. 3, che-
lation of extracellular Ca2 with EGTA inhibited
insulin-induced activation of PI 3-kinase by 85%.
We also tested the e¡ect of nickel, a divalent cation
blocker of Ca2 channels [30,31], and of gadolinium,
a trivalent ion of the lanthanide series previously
shown to inhibit non-selective cation channels in
hepatoma cells [32] and to interfere with Ca2 entry
caused by internal Ca2 store depletion in cultured
hepatocytes [33,34]. At respective doses of 500 WM
and 50 WM, both Ni2 and Gd3 inhibited insulin-
induced PI 3-kinase activation by 50% (Fig. 3). In
contrast, verapamil, an inhibitor of voltage-activated
Ca2 channels [35], did not signi¢cantly a¡ect the
stimulation of enzyme activity by insulin. Control
experiment also demonstrated that neither external
Ca2 chelation nor any of the pharmacological
agents a¡ected basal PI 3-kinase activity (results
not illustrated). The pharmacological pro¢le of the
PI 3-kinase response is similar to that obtained pre-
viously for insulin-induced stimulation of MAPK ac-
tivity [17] and thus suggests that Ca2 in£ux may
also play an important role in this other major sig-
naling pathway in liver cells [29].
Fig. 2. Dose-dependent e¡ect of insulin on PI 3-kinase activity.
Isolated hepatocytes were incubated with various concentrations
of insulin (0, 0.1, 1,10, 100 nM) for 3 min at 37‡C. PI 3-kinase
activity was measured as described in Section 2. The data
shown are the mean þ S.E.M. of 6 separate experiments and are
expressed in relation to respective baseline values obtained for
each experiment (di¡erent hepatocyte preparation).
Fig. 3. E¡ects of extracellular calcium chelation (EGTA) and of
calcium channel inhibitors on insulin-induced PI 3-kinase activ-
ity. Primary rat hepatocytes were pretreated for 15 min with or
without EGTA or the speci¢ed Ca2 channel inhibitors at the
indicated concentrations before stimulation with 10 nM insulin
for 3 min. Top: cells lysates were prepared and proteins were
immunoprecipitated with anti-p85-antibody, the immunocom-
plex was assayed for PI 3-kinase activity using PI as substrate
and [32P]ATP. The labeled phospholipids were resolved by thin
layer chromatography then exposed to X-ray ¢lm. An autora-
diogram of a representative experiment is shown. Arrow head
indicates the position of the phosphorylated phosphoinositide
products (PIP). Bottom: PIP’s formed in the above experiment
were quanti¢ed with a phosphorimager. Results are presented
as the mean þ S.E.M. of eight experiments and are expressed in
relation to baseline values obtained in respective controls. Dif-
ferences between treatment groups were determined by analysis
of variance. *Signi¢cantly di¡erent from control, 2Signi¢cantly
di¡erent from insulin, P6 0.002.
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3.4. E¡ect of Ca2+ on insulin-induced tyrosine
phosphorylation of IR L-subunit and of IRS-1
Moving upstream in the insulin signaling cascade,
we next evaluated the implication of Ca2 move-
ments in the insulin-induced phosphorylation of
both IRS-1 and IR L-subunit. Hepatocytes were
again stimulated for 3 min with 10 nM insulin. As
shown in Fig. 4, insulin induced a stimulation of
IRS-1 tyrosine phosphorylation as expected. There
was no statistical signi¢cant di¡erence in the tyrosine
phosphorylation of IRS-1 in groups pretreated with
EGTA, Ni2,Gd3 or verapamil as compared to
those stimulated with insulin alone.
Fig. 5 presents the results obtained for IR L-sub-
unit tyrosine phosphorylation. As expected, stimula-
tion of hepatocytes with 10 nM insulin for 3 min
yielded a signi¢cant increase in the amount of tyro-
sine-phosphorylated IR L-subunit. However as ob-
served with IRS-1, chelation of external Ca2 or pre-
treatment with Ni2, Gd3 or verapamil did not
signi¢cantly in£uence this action of insulin as ascer-
tained by one-way ANOVA.
4. Discussion
The implication of intracellular Ca2 as a mediator
in insulin action was originally proposed by Clausen
Fig. 4. E¡ects of external Ca2 chelation and of Ca2 channel
inhibitors on insulin receptor substrate-1 tyrosine phosphoryla-
tion. Primary rat hepatocytes were pretreated for 15 min with
the various agents at the indicated concentration before stimu-
lation with 10 nM insulin for 3 min. The cells were lysed and
then subjected to immunoprecipitation with an antibody to
IRS-1 followed by immunoblotting with antiphosphotyrosine
antibody. (A) Representative immunoblot of eight experiments
with similar results. (B) The tyrosine phosphorylation of IRS-1
bands were quanti¢ed by densitometric analysis using NIH im-
ager. Results are expressed as the mean þ S.E.M. of eight ex-
periments.
Fig. 5. E¡ects of external Ca2 chelation and of Ca2 channel
inhibitors on insulin-induced tyrosine phosphorylation of insulin
receptor. The cells were treated as described in Fig. 4. The cells
were lysed and subjected to immunoprecipitation with anti-hu-
man antibody to IR L-subunit followed by immunoblotting
with anti-phosphotyrosine antibody as described in Section 2.
(A) The immunoblot is representative of one of six independent
experiments with similar results. (B) The bands were quanti¢ed
as described in Fig. 4. Results are expressed as the mean þ
S.E.M. of six experiments.
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and colleagues in 1974 [36]. Insulin was later shown
to increase intracellular Ca2 in normal human adi-
pocytes [37] and in vascular smooth muscle cells [38],
but not in a skeletal muscle cell line [39]. In liver
cells, it was shown that the insulin-dependent stim-
ulation of phosphodiesterases, of succinate oxidation
and of protein synthesis was inhibited by the lack of
external Ca2 [40,41]. In 1985, Strunecka presented
indirect evidence that insulin elevated steady-state
Ca2 in digitonin-permeabilized rat hepatocyte sus-
pensions [42]. Our laboratory recently demonstrated
that insulin induces an in£ux of extracellular Ca2
into primary cultures of rat hepatocytes [17]. We also
found that interference with insulin-induced Ca2
movements, using external Ca2 chelation or Ca2
channel inhibitors, blocked the hormone’s ability to
stimulate MAPK activity [17]. These data are in line
with recent evidence showing that MAPK activity in
rat hepatocytes can be modulated by Ca2-depen-
dent mechanisms [43] as seen in other epithelial cells
[44]. Thus, our results strongly indicated that insulin-
induced Ca2 in£ux was a crucial component for at
least part of the insulin signaling cascade in rat liver
cells. We thus sought to determine if other compo-
nents of this signaling cascade were also Ca2-de-
pendent.
The early events occurring after insulin binding
have been rather well documented in the liver of
intact animals [45^47]. IRS-1 has been shown to be
a major and direct substrate of the activated insulin
receptor both in vivo and in vitro [9,48]. IRS-1 has
multiple potential tyrosine phosphorylation sites
which, once phosphorylated, serve as intracellular
binding sites for proteins containing SH2 domains
[3,6,9,49,50]. For instance, tyrosine phosphorylation
of IRS-1 leads to its association with the enzyme PI
3-kinase [3,8,9,51] resulting in an increase in total PI
3-kinase activity in several cell types [3,8,9,23,24,50].
Studies based on the use of the inhibitors wortman-
nin and LY294002 reported that PI 3-kinase is in-
volved in the stimulation of glucose uptake and acti-
vation of glycogen synthase induced by insulin in
either cultured hepatocytes or in the whole liver, re-
spectively [52^54]. Thus, the activation of PI 3-kinase
by insulin in liver cells is physiologically relevant and
we assessed the possible implication of Ca2 in this
insulin action.
The results presented herein con¢rm, by using a
direct immune-complex enzyme assay, that PI 3-ki-
nase activity is increased by insulin in primary hepa-
tocytes, as seen previously for isolated rat adipocytes
[24]. PI 3-kinase activity was also detected in the
basal state. Time course data and insulin dose^re-
sponse relationship show that hepatocyte PI 3-kinase
responds rapidly to physiologically relevant concen-
trations of the hormone.
We next evaluated the implication of Ca2 ions in
the insulin-dependent stimulation of PI 3-kinase ac-
tivity in isolated cultured rat hepatocytes. The results
demonstrate that conditions previously shown to in-
hibit insulin-induced Ca2 in£ux, namely EGTA,
Ni2 and Gd3, also blocked the stimulation of PI
3-kinase by the hormone, whereas verapamil was in-
e¡ective. This pharmacological pro¢le is identical to
the one we recently observed for the insulin-depen-
dent stimulation of MAPK activity [17]. This
strongly suggests that Ca2 in£ux also plays an im-
portant role in PI 3-kinase activation, another major
signaling pathway of insulin in liver cells [29].
We also evaluated the implication of Ca2 move-
ments in the insulin-induced phosphorylation of IR
L-subunit and of IRS-1, two early steps in the insulin
signaling cascade that have been de¢ned at the mo-
lecular level and that are essential for mediating sev-
eral biological responses to insulin. In contrast to PI
3-kinase, insulin-dependent tyrosine phosphorylation
of IR L-subunit and of IRS-1 was una¡ected by ex-
ternal Ca2 chelation or by the Ca2-channel block-
ers Ni2 and Gd3. One interpretation of our data is
thus that insulin-induced Ca2 in£ux may intervene
in the insulin signaling cascade between IRS-1 and
downstream elements, such as PI 3-kinase and
MAPK.
Indeed, it was shown that PI 3-kinase activity may
be modulated by Ca2 [55] through a Ca2-depen-
dent interaction of calmodulin directly with the p110
catalytic subunit of the enzyme [56], as was also seen
with the SH2 domain of the p85 regulatory subunit
[57]. Moreover, Ca2-dependent conformational
changes of the N-terminal SH2 domain of p85 were
reported to be important for PI 3-kinase binding to
K-PDGF receptor [58] and Ca2 ions were found to
directly activate puri¢ed PI 3-kinases in bovine thy-
mus [59].
A number of studies also point to a relationship
between PI 3-kinase and MAPK pathways. For in-
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stance, wortmannin was shown to prevent the stim-
ulation of MAPK isoform ERK-1 by insulin in a
primary hepatocyte model similar to our own, sug-
gesting that PI 3-kinase activity may lie upstream of
MAPK in liver cells [60]. In addition, PI 3-kinase can
form a complex with Ras [61] while expression of a
constitutively active p110 catalytic subunit of PI
3-kinase can accentuate Ras-dependent cellular pro-
cesses [62], including MAPK activation. Hence, it is
possible that the insulin-induced in£ux of Ca2 ob-
served previously by our laboratory [17] stimulates
PI 3-kinase activity which, in turn, triggers the
MAPK cascade.
An interesting alternative explanation for our re-
sults would implicate recently identi¢ed Ca2-de-
pendent tyrosine kinases of the focal adhesion kinase
family, such as Pyk2 [63], which are known to medi-
ate Ca2-dependent MAPK activation in certain cell
types [64]. Pyk2 or Pyk2-like kinases appear to be
activated early in receptor signaling cascades. For
instance, Ca2-dependent tyrosine phosphorylation
of SHC by Pyk2 has been reported [65] and down-
stream activation of both PI 3-kinase and MAPK
could thus ensue. Hence, inhibition of insulin-in-
duced Ca2 in£ux by EGTA or channel blockers
could prevent Pyk2 activation. Finally, although
the phosphorylation of the insulin receptor and of
IRS-1 are not a¡ected by our experimental modula-
tion of Ca2 in£ux, our results do not rule out that
prevention of Ca2 in£ux may interfere with the for-
mation of complexes between IRS-1 and other e¡ec-
tors, such as GRB2 or the p85 regulatory subunit of
PI 3-kinase. Further experiments will be necessary to
elucidate the exact site of action of Ca2 in£ux in the
insulin signal transduction cascade.
The means by which insulin triggers Ca2 in£ux
into liver cells is also unclear. The pharmacological
sensitivity of this in£ux and of insulin-stimulated PI
3-kinase and MAPK activities is compatible with
that of non-selective cation channels present on hep-
atocytes [18]. It is thus possible that these channels
mediate the e¡ect of insulin on hepatocellular Ca2,
as supported by our preliminary observations using
the patch clamp technique [66]. Coupling between
the insulin receptor and cation channels is not un-
precedented since insulin was shown to activate a 10-
pS calcium-permeable channel in CHO-IR cells [67].
Moreover, this coupling was physiologically relevant
since Ni2 inhibition of this channel abolished the
e¡ect of insulin on DNA synthesis [67].
In conclusion, our study demonstrates that inter-
ference of insulin-induced Ca2 in£ux into primary
rat hepatocytes prevents the activation of PI 3-kinase
by the hormone, but not the associated tyrosine
phosphorylation of insulin receptor L-subunit or of
IRS-1. Hence, Ca2 ions may intervene in the insulin
signaling cascade downstream of IRS-1 or at an in-
dependent site upstream of both PI 3-kinase and
MAPK in hepatocytes. Our studies are within the
physiological framework since both PI 3-kinase and
MAPK activities were shown to be important for the
stimulation of glycogen synthesis by insulin in liver
cells [54]. Our results thus support the notion that
insulin-induced Ca2 movements are a crucial part
of the physiological action of this hormone in the
liver.
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